Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
The jury is in – usual gout care isn’t working well, especially for Māori and Pacific peoples, who are disproportionately affected by this common disorder.
What potential tools are readily available to reduce gout harm? Specific clinician actions!
Read the bulletin to find out more.
Looking for up-to-date information on gout? You can find it here!
We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.
Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.
The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.
We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.
Introducing Legendary Conversations, our podcast series that explores aspects of primary care in Aotearoa New Zealand. In episode one (part 1), we talk with Professor Keith Petrie about the psychological effects of taking medicines, and what primary healthcare professionals need to know.
Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and with drug-related morbidity and mortality. As such, it needs to be addressed holistically as part of the psychosocial medical model.
Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.
As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.
Read the HAH Bulletin to find out more.
Since originally publishing this article in September 2021, selegiline has been discontinued and supplies have been depleted. Rasagiline is now the only funded MAO-B inhibitor available in New Zealand.
This resource provides advice on prescribing and supplying rasagiline, which is currently funded but not yet approved by Medsafe.
In this webinar, Dr Ryan Paul discusses the newly-funded type 2 diabetes medication dulaglutide, and provides advice on when and how to use it.
Dulaglutide is available from 1 September, but do you know how to pronounce it? Listen to our quick guide for help.
When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).
Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk.
In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.
When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,1 choice is based primarily on predominant comorbidities, clinical features and tolerability.
Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ.
Read the HAH Bulletin (updated July 2022) to find out more.